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Abstract 
 
Accumulating evidence indicates that infiltrating stromal cells contribute directly and 
indirectly to tumor growth in a wide range of cancers. In follicular lymphoma (FL), 
malignant B cells are found admixed with heterogeneous lymphoid-like stromal cells 
within invaded lymph nodes and bone marrow (BM). In addition, mesenchymal 
stromal cells (MSC) support in vitro FL B-cell survival, in particular after their 
engagement towards lymphoid differentiation. We show here that BM-MSC obtained 
from FL patients (FL-MSC) display a specific gene expression profile compared to 
MSC obtained from healthy age-matched donors (HD-MSC). This FL-MSC signature 
is significantly enriched for genes associated with a lymphoid-like commitment. 
Interestingly, CCL2 could be detected at a high level within FL cell niche, is 
upregulated in HD-MSC by coculture with malignant B cells, and is overexpressed by 
FL-MSC, in agreement with their capacity to recruit monocytes more efficiently than 
HD-MSC. Moreover, FL-MSC and macrophages cooperate to sustain malignant B-
cell growth whereas FL-MSC drive monocyte differentiation towards a proangiogenic 
and LPS-unresponsive phenotype close to that of tumor-associated macrophages. 
Altogether, these results highlight the complex role of FL stromal cells that promote 
direct tumor B-cell growth and orchestrate FL cell niche, thus emerging as a potential 
therapeutic target in this disease. 
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Introduction 
 
Tumorigenesis is widely recognized as a non cell-autonomous process depending on 
an intricate network of surrounding accessory supportive cells1. Among this 
neoplastic microenvironment, cancer-associated fibroblasts (CAF) are phenotypically 
and functionally distinct from their normal counterpart, thus providing a niche-based 
model of oncogenesis resulting from the dynamic co-evolution of both cancer and 
stromal cells2,3. CAF phenotype and molecular signatures are strongly 
heterogeneous but are generally maintained in culture, implying stable alterations. 
This heterogeneity could be associated in part to tumor type and localization but is 
also probably ascribed to the diverse origins of CAF, which have been reported to 
derive from resident local fibroblasts, from bone marrow (BM)-derived mesenchymal 
progenitors, or from passenger stromal cells brought with tumor cells. In particular, 
mesenchymal stromal cells (MSC) could be recruited within tumors where they 
incorporate into the stroma, become activated, and potentiate tumor growth in co-
injection studies4. MSC have been shown to differentiate into CAF-like cells in vitro 
after exposure to cancer cell conditioned medium5 and to stimulate tumor survival 
and proliferation, angiogenesis, and metastastic spread in experimental xenograft 
models6,7. Even if few data are available on MSC derived from cancer patients, BM-
MSC from patients with multiple myeloma (MM) were shown to have a distinct 
molecular signature and to support more efficiently the growth of malignant plasma 
cells than BM-MSC obtained from healthy donors (HD)8. 
Interestingly, it was recently demonstrated that solid tumors could direct the 
reorganization of surrounding stroma into lymphoid-like stromal structures involving 
fibroblastic reticular cells (FRC)-like cells9,10. Within normal lymph node (LN), FRC 
produce and ensheathe collagen bundles and other extracellular matrix components, 
building an enclosed conduit system involved in the delivery of small molecules, such 
as chemokines and antigens, to the T-cell zone. Moreover, FRC provide a foothold 
for immune cell recruitment, motility, interaction, and homeostasis11. We have 
previously demonstrated that LN contained bona fide MSC and that human BM-MSC 
as well as LN-MSC could be committed to FRC differentiation in response to a 
combination of tumor necrosis factor alpha (TNF) and lymphotoxin alpha1beta2 (LT), 
the two main factors involved in the differentiation and maintenance of secondary 
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lymphoid organs12. Nevertheless, the precise relationships between MSC, FRC, and 
CAF remain elusive.  
Follicular lymphomas (FL) are the most frequent indolent non-Hodgkin's lymphomas 
(NHL) and result from the transformation of germinal center (GC)-derived B cells 
retaining a strong dependence on their specific lymphoid microenvironment13. In 
agreement, gene expression profiling (GEP) revealed that the outcome of patients 
with FL is primarily predicted by specific gene signatures of non-malignant tumor-
infiltrating cells14. More recently, immunohistochemical studies have proposed a large 
panel of predictive markers reflecting the number, activation, and/or spatial 
distribution of infiltrating immune cells, in particular T cells and tumor-associated 
macrophages (TAM)15. Concerning stromal cell niche in FL, FRC meshwork is 
expanded and activated within invaded LN16 and in vitro functional studies have 
underlined that mesenchymal cells recruit malignant B cells and protect them from 
spontaneous and drug-induced cell death12,17,18. In addition, stromal cells may also 
interact with FL infiltrating immune cells to indirectly favour lymphoma progression. 
Interestingly, FL is generally a disseminated disease with initial involvement of both 
LN and BM19. Moreover, BM infiltration is characterized by the ectopic development 
of lymphoid-like stromal cells of heterogeneous phenotype that are found admixed 
with malignant B cells20. Whether these cells actually arise from in situ differentiation 
of resident MSC is unknown. We previously showed that MSC-derived FRC-like cells 
display an increased capacity to sustain FL B-cell survival and that primary purified 
malignant B cells could promote FRC differentiation12. These results suggest that 
malignant B cells can endow their stromal microenvironment with supportive 
properties. Within the BM, malignant B cells retained their main follicular features and 
undergo independent intraclonal evolution21 suggesting that the BM provides a 
preferred non-lymphoid tumor microenvironment that would be very useful to study 
stromal alterations.  
To better understand characteristics and functions of stromal cells in FL we 
investigated GEP of BM-MSC from FL patients pertaining to lymphoid stroma 
signature and explored the functional implications of the specific FL-MSC signature. 
In particular, we highlighted the role of FL-associated stromal cells in the recruitment 
and polarization of monocytes into TAM-like cells. Combined with our previous 
studies, this work draw a more complete picture of how MSC contribute to FL 
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lymphomagenesis, through a dual role involving a direct B-cell supportive effect and 
an indirect activity on the orchestration of FL cell niche.  
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Materials and Methods 
 
Patients and cell samples 
Subjects were recruited under institutional review board approval and informed 
consent process according to the Declaration of Helsinki. BM aspirates were 
obtained from FL patients at diagnosis and from HD undergoing cardiac surgery. 
Clinical characteristics of the 10 FL patients used to obtain FL-MSC GEP are listed in 
Supplemental Table S1.  
BM plasma were collected by centrifugation and frozen until use. BM mononuclear 
cells (BM-MNC) were isolated by Ficoll density gradient and seeded at 104 cells/cm2 
in α-MEM (Life Technologies, Carlsbad, CA) supplemented with 10% screened fetal 
calf serum (FCS, Hyclone, Logan, UT), 100 IU/mL penicillin, 100 µg/mL streptomycin, 
and 1 ng/ml fibroblast growth factor 2 (FGF-2, R&D Systems, Abingdon, UK)22. Non 
adherent cells were discarded after 2 days of culture and adherent cells were 
replenished twice a week with fresh culture medium until confluence (P0). BM-MSC 
were then harvested using trypsin, and seeded at 500 cells/cm2 until confluence (first 
passage, P1). The frequency of colony-forming unit-fibroblast (CFU-F) in BM-MNC 
was evaluated in parallel for all MSC batches. At day 10, cells were stained with May-
Grunwald-Giemsa and colonies with more than 50 cells were counted. The growth 
kinetic was assessed by the number of population doubling (PD) calculated as: 
Log(number of cells at the end of passage/number of seeded cells)/Log2, where the 
number of seeded cells for P0 was the number of CFU-F within BM-MNC. The 
complete phenotype of all HD-MSC and FL-MSC batches was performed at the end 
of P1 before microarray experiments (see supplemental data). In addition, BM-MSC 
were used at passages 2 to 3 for functional studies. 
Primary malignant B cells from FL lymph nodes were purified by negative selection 
as described23. Peripheral blood monocytes were obtained by elutriation (J6 
centrifuge, Beckman Coulter, Villepinte, France) followed by an additional depletion 
of residual T cells using anti-CD3 microbeads (Miltenyi Biotech, Bergisch Gladbach, 
Germany). Only cell fractions with at least 98% cell purity as evaluated by flow 
cytometry were used for further experiments. BL2, VAL, and RL GC-derived 
lymphoma B-cell lines were maintained in RPMI1640-10% FCS. 
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GEP study 
GEP was performed on 10 BM-MSC obtained from FL patients (FL-MSC) and from 6 
age-matched HD (HD-MSC) treated or not for 3 days by TNF (10ng/mL) and LT 
(100ng/mL, R&D Systems, Abingdon, UK) to induce their FRC-like differentiation12. 
RNA was extracted using AllPrep ARN/ADN/protein kit (Qiagen, Valencia, CA) and 
RNA purity and integrity was checked using the Bioanalyzer 2100 (Agilent, Santa 
Clara, CA). All samples used for microarray experiments displayed a RNA integrity 
number (RIN) above 8.9. Biotinylated cRNA were amplified according to the small 
sample labelling protocol (TwoCycle amplification kit, Affymetrix, Santa Clara, CA) 
and hybridized on GeneChip HG-U133 Plus 2.0 oligonucleotide microarrays 
(Affymetrix). Data analyzes were performed using Partek Genomics Suite (Partek, St 
Louis, MO) as described in Supplemental data. All microarray data are available on 
the Gene Expression Omnibus (GEO) under accession number GSE35331 
 
Real-time quantitative PCR (RQ-PCR) 
cDNA synthesis was performed on 1µg total RNA using the Superscript II reverse 
transcriptase and random hexamers (Invitrogen, Carlsbad, CA). We used then 
specific Taqman Gene Expression Assays (Supplemental Table S2) and the TaqMan 
Universal master mix (Applied Biosystems, Foster City, CA). GAPDH was determined 
as an appropriate internal standard gene. Gene expression was measured using the 
ABI Prism 7700 Sequence Detection System based on the ΔCT calculation method.  
 
B-cell growth assays 
After serum deprivation, BL2 (2.5 x 104 cells/mL), RL, or VAL (1.25 x 104 cells/mL) 
were seeded with low serum concentration in the presence or not of a confluent MSC 
monolayer pretreated or not with TNF/LT for 3 days. When indicated, we used as 
feeder cells in vitro differentiated macrophages, obtained by a 4-day culture of 
purified monocytes with 10 ng/mL macrophage-colony stimulating factor (M-CSF, 
R&D Systems) in the presence or not of FL-MSC (ratio 3/1). MSC and macrophages 
were extensively washed before the 3-day coculture with B cells. Cells were pulsed 
with 1µCi/well tritiated thymidine (3H-TdR, Perkin Elmer, Courtaboeuf, France) for the 
last 16 hours of culture, harvested, and counted on a liquid scintillation analyzer. For 
primary FL samples, purified malignant B cells (7.5 x 105 cells/mL) were seeded in 
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RPMI1640-10% FCS in the presence or not of FL-MSC and/or macrophages. After 7 
days of culture, non-adherent and adherent cells were collected, pooled, and the 
absolute number of CD19/CD20posCD105negCD14neg TOPRO-3neg viable B cells was 
evaluated using FlowCounts beads (Beckman Coulter).  
 
B-cell proliferation and apoptosis 
VAL and RL were cultured with low serum concentration alone or in the presence of 
confluent FL-MSC, in vitro differentiated macrophages, or both. After 24h, cell 
apoptosis was analyzed using active caspase-3 staining gated on CD19/CD20pos B 
cells. In the same experiments, cell proliferation was analyzed after 3 days using 
BrdU staining. Briefly, cells were pulsed with 10µM BrdU (Becton Dickinson) for 30 
minutes before cell harvesting and quantification of the percentage of BrdUpos cycling 
cells among CD19/CD20posactive caspase-3neg viable B cells. 
 
CCL2 quantification 
CCL2 was quantified using the DuoSet ELISA kit (R&D Systems) in BM plasma, in 
the supernatants of HD-MSC and FL-MSC collected at the end of P1, and in the 
supernatant of HD-MSC stimulated with TNF/LT or cocultured with RL, VAL, BL2, or 
purified primary B cells for 3 days.  
In order to confirm the stromal origin of secreted CCL2 in B-cell/MSC coculture, both 
CD19/CD20posCD105negDAPIneg viable B cells and CD19/CD20negCD105posDAPIneg 
viable MSC were sorted using a FACSAria cell sorter (Becton Dickinson, San Diego, 
CA) at the end of the coculture and used to assess CCL2 mRNA expression by RQ-
PCR.  
In addition, HD-MSC were cocultured with VAL and RL for 3 days before collection of 
the supernatant and cell detachment by trypsin. After depletion of residual B cells 
using anti-CD45 Dynabeads (Invitrogen), HD-MSC cells were seeded again in culture 
for 10 days at confluence. Supernatants were collected at day 3 and 10 for CCL2 
quantification by ELISA.  
 
Migration assay 
Purified monocytes (105 cells/100µL) were added in RPMI1640-1% FCS (migration 
medium) to the upper compartment of Transwell chambers with 5-µm pore filters 
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(Costar). Lower chambers contained supernatants obtained after 4 days of culture in 
migration medium of FL-MSC, HD-MSC, or HD-MSC prestimulated by RL or VAL B-
cell lines for 3 days. When indicated, CCL2 was depleted from MSC supernatants. 
The absolute number of viable monocytes was quantified in the lower chamber after 
1.5 hour using FlowCount beads.  
 
Macrophage polarization 
Purified monocytes (1.5 x 105 cells/cm2) were cultured alone or with MSC (5 x 104 
cells/cm2) in the presence of M-CSF. After 1 day of coculture, TNF and IL-10 were 
quantified in cell supernatants using specific ELISA assays (R&D Systems and 
Becton Dickinson; respectively). In parallel, cells were harvested and the expression 
level of HLA-DR, CD86, and CD14 was evaluated by flow cytometry on 
CD14posCD105negTOPRO-3neg cells as the ratio of the mean of fluorescence intensity 
(rMFI) compared to isotype-matched controls. In addition, after 7 days of coculture, 
cells were stimulated or not with 100ng/mL LPS (Invivogen, San Diego, CA) for 5 
hours before cell-sorting of CD14posCD105negTOPRO-3neg viable macrophages. RNA 
was then extracted for RQ-PCR experiments. When specified, the γ-secretase 
inhibitor DAPT (25µM, Calbiochem, San Diego, CA) was added to evaluate the role 
of the Notch pathway. In this case, cell supernatants were collected 18 hours after 
LPS stimulation for measurement of TNF by ELISA. 
 
Statistical analyses 
Statistical analyses were performed with Prism software (GraphPad Software, La 
Jolla, CA) using the Wilcoxon or Student's t test for matched pairs or using the Mann-
Whitney nonparametric U test as appropriate. 
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Results 
 
FL-MSC display a specific gene expression profile 
BM-MSC were successfully obtained from all 6 HD and 10 FL patients and the 16 
MSC batches displayed similar cell morphology and phenotype including a lack of 
CD45, CD14, CD34, and CD31 together with a strong expression of CD73, CD90, 
and CD105 (Figure S1 and Table 1). Moreover, no contamination by CD19pos B cells 
could be detected at the end of P1. As BM-MSC growth has been correlated with the 
age of donors24, we selected age-matched HD (Table 1). In these conditions, neither 
the CFU-F concentration in the BM nor the cumulative population doubling of BM-
MSC significantly differed between HD and FL patients. Challenging data suggested 
that CAF undergo genetic alterations during tumor progression3 and microvascular 
endothelial cells in B-cell lymphomas were reported to harbor lymphoma-specific 
chromosomal translocations25. However, we observed no karyotypic abnormality in 
HD- or FL-MSC and FISH analysis for t(14;18) gave consistently negative results 
including in FL-MSC obtained from patients with t(14;18)pos malignant B-cell clones 
(Figure S2). Recent studies have demonstrated that senescent cells secrete a 
complex set of proinflammatory and tumor promoting factors26. However, HD-MSC 
and FL-MSC displayed no β-galactosidase staining at the end of P1 (data not shown) 
and expressed a very low level of CDKN2A, the gene coding for the MSC 
senescence marker p16INK4a (Figure S3) suggesting that they were not engaged into 
a senescence process24.  
The GEP of resting HD-MSC and FL-MSC was determined at the end of P1 using 
Affymetrix U133 Plus 2.0 microarrays. Raw data were normalized using GC-RMA 
method and filtered to select the 9967 probesets (PS) showing the highest variation 
coefficient between samples. Strikingly, unsupervised hierarchical clustering analysis 
on this restricted dataset was able to perfectly segregate FL-MSC from HD-MSC 
(Figure 1a). To further delineate the specific GEP of FL-MSC, we then performed a 
supervised analysis by combining an asymptotic unpaired Mann-Whitney test and a 
SAM method. Based on this approach, we highlighted 408 PS representing the FL-
MSC signature and corresponding to 320 upregulated genes and 60 downregulated 
genes (Figure 1b and Table S3). Among them, 16% were classified as coding for 
extracellular space or plasma membrane proteins (Figure S4). Interestingly, Ingenuity 
Pathway Analysis of this 408-PS list pointed out that the most significantly enriched 
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biological functions were linked to hematological system development and function, 
hematopoiesis, and immune cell trafficking. The expression level of six genes was 
validated by RQ-PCR and yielded concordant results. For this specific analysis, we 
selected two genes coding for factors potentially implicated in B-cell adhesion and 
growth (CHST2 and CLU), one gene involved in cell proliferation and differentiation 
(DUSP6), and three genes regulating host/tumor interface (TNFRSF10A, TLR4, and 
CCL2). Among them, CCL2 was the most significantly differentially expressed genes 
between FL-MSC and HD-MSC (Figure 1c). 
 
FL-MSC are committed to a FRC-like phenotype 
In FL, invaded BM is infiltrated by lymphoid-like stromal cells of heterogeneous 
phenotype and unknown origin and function. We thus decided to examine if FL-MSC 
actually displayed some common genetic features with FRC. We first established the 
gene expression pattern of human FRC-like cells through the analysis of HD-MSC 
treated by TNF/LT for 3 days, a stimulation process previously associated with the in 
vitro differentiation into functional FRC-like cells12. After filtering the 8340 PS with the 
highest variation coefficient between samples, we underlined, by combining a paired 
t-test and a SAM method, 1673 PS representing the TNF/LT signature and 
corresponding to 811 upregulated genes and 431 downregulated genes (Figure 2a 
and Table S4). The expression level of seven genes identified by microarray strategy 
as highly induced by TNF/LT stimulation was validated by RQ-PCR (Figure 2b). 
Interestingly, TLR4 and CCL2 have been already pinpointed in the FL-MSC 
signature. Moreover, we also confirmed the upregulation of IL6, HBEGF, IL15, IL8, 
and CCL5 that were all involved in the recruitment and/or activation of immune cells.  
We next performed a Gene Set Enrichment Analysis (GSEA) approach in order to 
specifically assess the over-representation of the TNF/LT signature in FL-MSC. 
Interestingly, we found that FL-MSC GEP was significantly enriched in genes 
overexpressed in HD-MSC treated with TNF/LT (Figure 2c). In addition, among the 
105 genes that were simultaneously found within the TNF/LT and the FL-MSC 
signatures, 101 were coordinately upregulated or downregulated in both HD-MSC 
treated by TNF/LT and FL-MSC (Figure S5 and Table S5). Finally, unsupervised 
hierarchical clustering revealed that the TNF/LT signature was sufficient per se to 
adequately segregate HD-MSC from FL-MSC (Figure 2d).  
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As FL-MSC and HD-MSC have distinct molecular profiles, we performed functional 
coculture experiments to compare their respective capacity to reverse serum 
deprivation-induced growth arrest of GC-derived malignant B-cell lines. As previously 
reported12, HD-MSC efficiently sustained the growth of neoplastic B cells, and 
preliminary treatment by TNF/LT reinforced this feeder effect by 2-fold (P < .01; 
Figure 2e). Importantly, resting FL-MSC exhibited a significantly better B-cell 
supportive activity than HD-MSC (13310 cpm [7266-18400] versus 6663 cpm [5374-
8264], P < .001) thus limiting the additional effect of TNF/LT prestimulation of FL-
MSC to a 1.26-fold increase. Altogether, these data argued for commitment of FL-
MSC towards a FRC-like phenotype consistent with their increased capacity to 
promote malignant B-cell growth. 
 
Monocytes are specifically recruited by FL-MSC and support FL cell growth 
We decided to focus on CCL2 as the master upregulated gene in FL-MSC and a 
high-ranked member of the TNF/LT signature. We first demonstrated that CCL2 was 
produced at a higher level in the supernatant of FL-MSC compared to HD-MSC 
(Figure 3a). Moreover, we quantified CCL2 in the BM plasma from 26 FL patients and 
31 HD by ELISA and showed that CCL2 levels were variably but highly significantly 
increased in invaded BM compared to normal BM (474.4 pg/mL [5-4413] versus 33.6 
pg/mL [5-126.1]; Figure 3b), indicating that CCL2 could play a role in vivo within 
malignant cell niche. Of note, the three patients with FL grade 3a did not display a 
different CCL2 level in BM plasma compared to the 23 patients with FL grade 1-2. 
CCL2 had no direct impact on lymphoma B-cell chemotaxis or survival as evaluated 
using both GC-derived B-cell lines and primary purified FL B cells (data not shown). 
However, FL-MSC recruited monocytes more efficiently than HD-MSC (Figure 3c). 
To ascertain whether CCL2 contributed to FL-MSC-dependent monocyte migration, 
we specifically depleted CCL2 from MSC supernatants. Interestingly, CCL2 depletion 
abolished monocyte recruitment. Taken together these results argued for a role of 
MSC-derived CCL2 on the cellular composition of FL microenvironment by attracting 
monocytes rather than for a direct activity on B-cell growth. 
A high level of TAM has been correlated with bad outcome in patients with FL treated 
with chemotherapy27 but their involvement in FL B-cell growth has never been 
studied. We thus explored the growth-promoting activity of in vitro differentiated 
macrophages on 2 GC-derived B-cell lines. Macrophages sustained the growth of 
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VAL and RL cell lines in low serum concentration as efficiently as FL-MSC. 
Moreover, FL-MSC and macrophages, previously maintained in coculture for 4 days 
to allow their crosstalk in vitro, exhibited a synergistic activity on malignant B-cell 
growth (Figure 4a). To further unravel the mechanism of this synergy, we specifically 
investigated both the survival and the proliferative capacities of FL-MSC, 
macrophages, and the combination of these two cell populations. Active caspase-3 
staining revealed that FL-MSC abrogated spontaneous VAL B-cell apoptosis 
whereas the protective effect of macrophages was significantly lower (42.9 ± 18% for 
B cells alone versus 8.4 ± 1.5% with FL-MSC versus 19.3 ± 3.9% with macrophages, 
P <.05, Figure 4b). In contrast, when considering the percentage of BrdUpos viable B 
cells, macrophages, unlike FL-MSC, increased VAL B-cell line proliferation (Figure 
4c). Similar results were obtained using RL cell line (data not shown). Primary FL B 
cells are poorly proliferating and highly prone to apoptosis in vitro. In accordance, we 
were able to confirm the survival potential of FL-MSC and macrophages on malignant 
B cells purified from 4 unselected FL patients but we could not detect any additional 
proliferative activity of the combination of both cell subsets (Figure 4d). Overall, these 
data supported the hypothesis that FL-MSC and macrophages cooperated to sustain 
malignant B-cell growth through protection from apoptosis and enhancement of 
proliferation. 
 
MSC drive monocyte differentiation towards a TAM-like phenotype 
BM-MSC affect the differentiation and function of dendritic cells and mature 
macrophages in vitro28. In addition, umbilical cord blood-derived MSC were recently 
reported to strongly reduce the T-cell stimulatory capacity of monocytes29. We 
therefore studied the phenotype of monocytes cocultured for 24h and 7 days with FL-
MSC. After 24h, FL-MSC increased the expression of HLA-DR, CD86, and CD14 on 
monocytes and modulated their secretory profile through a strong inhibition of TNF 
secretion together with an increased of IL-10 release (Figure 5a). In addition, IL10, 
IL6, and VEGFA, which have already been involved in the proangiogenic and 
protumoral activity of TAM in several tumor models, were upregulated after 7 days of 
coculture in cell-sorted differentiated macrophages (<0.5% MSC contamination, 
Figure 5b). Interestingly, we reported for the first time the strong induction (519 fold 
[23-1160], n=9) of PGF, the gene coding for placental growth factor, a member of the 
VEGF family that binds VEGFR-1 and forms functionally active heterodimers with 
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VEGF-A30. We next decided to evaluate the responsiveness of macrophages 
maintained in culture with FL-MSC to proinflammatory stimuli. Macrophages purified 
by cell-sorting after 7 days of coculture with FL-MSC have a reduced capacity to 
express pro-inflammatory and anti-inflammatory cytokines in response to LPS (Figure 
5c). Similar results were obtained using HD-MSC and FL-MSC from grade 1, grade 
2, and grade 3a FL patients (Figure S6). 
The Notch pathway regulates cell differentiation, proliferation, and survival in 
numerous contexts. Notch1-4 receptors interact with Notch ligands of the Jagged and 
Delta-like families leading to the proteolytic cleavage of the Notch receptor by the γ-
secretase, followed by the nuclear translocation of intracellular Notch domain. 
Recently, it has been reported that human BM-MSC and adipose tissue-derived MSC 
strongly express Jagged-1 and that Notch signaling is involved in their T-cell 
suppressive activity31,32. To explore the involvement of the Jagged/Notch interaction 
in the unresponsiveness of MSC-treated macrophages to LPS stimulation, we added 
DAPT, a highly selective γ-secretase inhibitor, during macrophage/MSC coculture. As 
shown in Figure 5d, the addition of DAPT significantly enhanced the capacity of 
macrophages cultured with FL-MSC to produce high amounts of TNF in response to 
LPS stimulation (1814 ± 1198 pg/mL with DAPT versus 530 ± 374 pg/mL with DMSO 
versus 442 ± 186 pg/mL with medium; n = 10). Interestingly, the production of IL-10 
in response to LPS was also restored when the Notch pathway was inhibited during 
MSC/macrophage coculture (data not shown). HD-MSC modulated similarly the 
response of macrophages to LPS stimulation (data not shown). 
In summary, monocytes exhibited a CD14hiCD86hiHLA-DRhiTNFloIL-10hi phenotype 
after a short course coculture with FL-MSC and HD-MSC and differentiated in 7 days 
into macrophages expressing high levels of proangiogenic factors and unresponsive 
to LPS stimulation. These data were strongly in favor of a TAM-like polarization. 
 
FL B cells promote CCL2 secretion by HD-MSC 
We next sought to assess whether malignant B cells could be involved in the 
overexpression of CCL2 by FL-MSC. For that purpose, HD-MSC were cocultured 
with TNF/LT as a positive control, as well as with various GC-derived B-cell lines and 
primary purified FL B cells. These experiments revealed an increased CCL2 
secretion in the presence of malignant B cells even if this induction was highly 
variable depending on the patient (from 1.1 to 42.3-fold, n = 16) and the cell line 
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tested (Figure 6a). Interestingly, the coculture of the same primary FL B-cells with 2 
different HD-MSC batches revealed intrinsically different capacity of malignant B cells 
to induce CCL2 production in HD-MSC with strong CCL2-inducers and poor CCL2-
inducers B cells. To unequivocally identify the source of CCL2 within the coculture, 
HD-MSC were cocultured with B-cell lines before cell-sorting of 
CD19/CD20posCD105neg B cells and CD19negCD105pos HD-MSC. RQ-PCR analysis 
confirmed the strong upregulation of CCL2 in HD-MSC, unlike in purified B-cell 
compartment (Figure 6b). We investigated whether induction of CCL2 production in 
HD-MSC by malignant B cells was maintained in culture in the absence of continuous 
B cell-dependent stimulation. Interestingly, 10 days after B-cell removal, HD-MSC 
retained an increased CCL2 production compared to pure HD-MSC, indicating that 
the effect of B cells was long-lasting (Figure 6c). Finally, we explored the functional 
relevance of this B cell-mediated CCL2 induction and demonstrated that conditioned 
media from HD-MSC/B-cell cocultures recruited more efficiently purified monocytes 
than HD-MSC supernatant (Figure 6d). 
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Discussion 
 
In this study, we identify the specific gene signature of BM-derived FL-associated 
stromal cells. We demonstrate that this signature is related to that of lymphoid-like 
stromal cells, suggesting an ectopic engagement to FRC differentiation in vivo. 
Interestingly the presence of lymphoid-like stromal networks has already been 
reported in murine models of solid cancers where they contribute to the induction of 
an immunotolerant microenvironment9,10. These cells are supposed to be locally 
induced during cancer-related inflammation and an inflammatory gene signature has 
also been highlighted in fibroblasts obtained from mammary and pancreatic tumors in 
mice and humans where they promote angiogenesis and inflammatory cell 
recruitment33. Nevertheless, lymphoid-like differentiation is not a common feature of 
stromal cells in hematological malignancies. In particular, the already reported 
specific GEP of multiple myeloma BM-MSC8 is not enriched for our FRC-like 
signature (data not shown), in agreement with the lack of morphologically detectable 
lymphoid-like structure in this disease. Importantly, in order to understand how 
malignant B cells could drive the emergence of an ectopic lymphoid-related stromal 
microenvironment, our study was performed on BM- unlike LN-MSC. However, CCL2 
is also overexpressed in stromal cells derived from FL LN compared to stromal cells 
derived from chronically inflamed tonsils (data not shown) suggesting a general role 
of CCL2 within stromal cell niche in FL that is not only related to cancer-related 
inflammatory process.  
We have previously demonstrated that FRC-like cells generated in vitro by 
stimulation of BM-MSC with TNF/LT are more powerful to drive malignant B cell 
survival than BM-MSC themselves12. Our current results reinforce and extend these 
data since we could establish that FL-MSC, already committed to a FRC-like 
differentiation, supported more efficiently the growth of malignant B cells. Similarly, 
MM-MSC were shown to overstimulate the proliferation of a MM cell line when 
compared to HD-MSC8. CCL2 had not direct impact on migration or survival of 
malignant FL B cells in agreement with the repression of CCR2 expression by Pax5 
B-cell transcription factor34. The mechanisms of the direct tumor-promoting capacity 
of FL-MSC remain thus to be identified. However, FL-MSC also displayed indirect 
pro-tumorigenic effects including an increased capacity to recruit monocytes in a 
CCL2-dependent manner. CCL2 is one of the most frequently observed chemokines 
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in a wide range of solid cancers where it harbors multifaceted activities by targeting 
both tumor cells and infiltrating myeloid cells. As an example, tumor-derived CCL2 
recruits monocytes and promotes their survival and their polarization into 
CD14posCD206pos M2-type macrophages in prostate cancer35. Moreover, CCL2 
synthetized by both the tumor and the stroma in a mouse model of breast cancer 
metastasis was recently involved in the early recruitment of CCR2pos VEGFAhi 
inflammatory monocytes that contribute to the extravasation and seeding of tumor 
cells36. In the same study, human inflammatory monocytes were shown to respond to 
the same CCL2-CCR2 axis for their recruitment into metastasis. Interestingly, it was 
recently suggested that perivascular BM stromal cells could sense circulating TLR 
ligands and, by producing CCL2, modulate the frequency of bloodstream 
inflammatory CCR2pos monocytes37. Our work reveals that BM-MSC could also 
induce CCL2-dependent monocyte migration in malignant context.  
MSC have been shown to produce a variety of anti-inflammatory mediators, including 
prostaglandin E2 and TNF-α stimulated gene 6 (TSG-6/TNFAIP6), that promote 
macrophage reprogramming associated with the release of IL-10 and the decrease of 
inflammatory cytokines29,38,39. In agreement, we demonstrate in our current study that 
HD-MSC and FL-MSC alter the phenotype and secretory profile of macrophages, 
leading to a polarization into TNFloIL-10hiVEGFAhiPGFhi LPS unresponsive TAM-like 
cells. Importantly, we highlight a key role for the Notch pathway in this process. In 
mouse macrophages, Notch activation promotes M1 polarization in response to LPS, 
a process supposed to be due to cooperation between Notch and NF-κB pathways40. 
However, in human macrophages, the functional outcome of TLR and Notch 
interactions is more complex since Notch target genes feedback and attenuate TLR-
induced cytokine production41. In addition, human adipose tissue-derived MSC 
mediate a Jagged-1 related inhibition of NF-κB signaling in T cells32. 
Besides the induction of a pro-angiogenic and anti-inflammatory profile on 
macrophages, coculture of MSC with macrophages give rise to a complex cell niche 
highly efficient in sustaining both survival and proliferation of malignant B cells. This 
synergy may be related to the crosstalk between the two cell partners, as recently 
suggested within hematopoietic stem cell niches where the interaction between 
macrophages and MSC regulates hematopoietic stem cell retention42. Multiple lines 
of evidence support the prominent role of TAM in the biology of FL, as highlighted by 
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the poor predictive value of a high content of CD68pos or CD63pos cells in patients 
treated with chemotherapy27,43. Moreover, the activation status of TAM is probably 
crucial in FL, as reported in several other cancers. In particular, the presence of 
STAT1pos TAM in FL was associated with an adverse outcome. Interestingly, the 
priming of macrophages with IFN-γ, which is overexpressed with FL 
microenvironment44, was shown to mediate a STAT1-dependent induction of CCR2 
associated with an increased migration in response to CCL245. Such activation loop 
should be important for the recruitment of macrophages in close vicinity to stromal 
cell/malignant B cell aggregates. The precise mechanisms of the supportive activity 
of macrophages towards neoplastic B-cell remain unknown even if their production of 
B cell-activating factor of the TNF family (BAFF) and a proliferation inducing ligand 
(APRIL) have been recently involved in diffuse large B-cell lymphoma and gastric 
mucosa associated lymphoid tissue (MALT) lymphoma46,47. Interestingly, we recently 
demonstrated that purified FL-TAM overexpress IL-15 that cooperates with T-cell 
derived CD40L signal to sustain FL cell growth48. A detailed analysis of FL-TAM 
would be very interesting to further understand their role in lymphomagenesis. 
A key unsolved issue is how tumor-infiltrating stromal cells acquire their pro-tumoral 
phenotype and what could be the role of tumor cells in this process. In MM, adhesion 
of malignant plasma cells to BM stromal cells triggers the NF-κB-dependent release 
of various cytokines, including IL-6 which in turn favors tumor cell growth49. Likewise, 
platelet-derived growth factor secreted by CLL B cells activates MSC to proliferate 
and produce VEGF, thus indirectly regulating angiogenesis and CLL disease 
progression50. Our results reveal that CCL2 is induced in HD-MSC by coculture with 
malignant B cells suggesting a bidirectional crosstalk between malignant B cells and 
stromal cells. We previously showed that FL B cells significantly overexpress TNF 
compared to normal tonsil B cells23 and the production of soluble TNF by normal B 
cells is essential for the proper organization of secondary lymphoid organ 
microarchitecture51. Since TNF/LT also induced CCL2 expression in MSC, it is 
tempting to speculate that TNF is, as least in part, involved in the upregulation of 
CCL2 by FL B cells. In agreement, antagonist anti-TNF receptor I protein strongly 
reduces the malignant B cell-driven induction of CCL2 production by MSC (Figure 
S7). The already described wide disparity of TNF expression by malignant B cells23 
could explain the strong variability of CCL2 induction in HD-MSC by FL B cells and 
could explain the heterogeneity of some functional data obtained in our study 
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whereas we could not found any link, in our limited patient series, between FL grade 
1 to 3a, that are now considered as equally indolent with indistinguishable clinical 
course52, and either MSC properties or CCL2 concentration in FL BM. A detailed 
analysis of the genes induced in stromal cells by contact with malignant B cells in 
response to TNF-dependent versus TNF-independent pathways is in progress. 
Besides malignant B cells, several other cell subsets could contribute to the 
modulation of FL-TAM phenotype and function. In particular, we recently unraveled a 
strong infiltration of invaded FL LN by IL-4-producing follicular helper T cells (TFH)53. 
In addition to its potential role in B-cell survival and proliferation, IL-4 is also known 
as a key inducer of TAM phenotype54. The presence and activation status of TFH or 
TFH-like cells within invaded BM are currently unknown.  
Altogether, these data highlight the complexity of FL tumors where stromal cells 
directly promote tumor growth and act also as global organizers of FL cell niches 
through the recruitment and polarization of macrophages. Additional experiments 
using purified FL-derived stromal cells obtained from invaded LN and BM would be 
helpful to address the specific role of MSC and their highly heterogeneous lymphoid 
progeny in FL development and drug resistance. The identification and 
characterization of this intricate network of cell interactions may provide novel 
strategies to disarm the tumor-promoting functions of stromal cells and could have 
significant therapeutic potential as a complement to conventional anti-lymphoma 
drugs. 
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Table 1. MSC growth and phenotype 
 
  Follicular lymphoma 
patients (n=10) 
Healthy donors 
(n=6) 
P value 
Sex ratio (M/F) 
 
 8/2 4/2  
Age *  
 
 58.5 (42-76) 54.0 (30-78)  
BM CFU-F * 
 
 52.5 (10.5-625) 161.7 (23.5-506) .3132 
Population 
Doubling * 
 
 
PD at P0 
PD at P1 
Total PD 
 
13.3 (11-15.1) 
5.1 (3-5.8) 
18.1 (14.1-20.9) 
 
12.7 (10.2-14.6) 
5.4 (4.3-6.1) 
18 (16.3-19.5) 
 
.8749 
.3831 
.8749 
Karyotype 
 
  
46, XX [30] (2) 
46, XY [30] (8) 
 
46, XX [30] (2) 
46, XY [30] (4) 
 
Phenotype at the 
end of P1 ** 
 
CD45 
CD19 
CD105 
CD90 
CD73 
 
0.2 (0-0.5) 
0.1 (0-0.3) 
99.9 (99.1-100) 
99.8 (99.5-100) 
99.8 (99.5-100) 
 
0.2 (0-0.2) 
0 (0-0.2) 
99.6 (99.3-100) 
99.9 (99.8-100) 
99.9 (99.5-100) 
 
 
* data are expressed as median (range)  
** data are expressed as median percentage (range) 
BM CFU-F = Number of CFU-F/10
6
BM mononuclear cells.  
Total population doubling (PD) = Cumulative number of PD (PD at P0 + PD at P1).  
Standard karyotype was performed at the end of P1 by analyzing 30 RHG-banded 
metaphases. 
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Figure Legends 
 
Figure 1. FL-MSC display a specific gene expression profile 
(a) Hierarchical clustering of resting untreated HD-MSC (n=6) and FL-MSC (n=10). 
Analysis was performed on the 9967 probesets (PS) showing the highest variation 
coefficient between samples. The relative level of gene expression is depicted 
according to the shown color scale. 
(b) Schematic representation of the statistical analysis used to highlight the FL-MSC 
signature defined as the intersection of the two genelists generated by SAM analysis 
(|FC|>2 and false discovery rate (FDR) < 5%) and Mann-Whitney rank test (|FC|>2 
and P < .05). 
(c) Validation by RQ-PCR of the overexpression of CHST2, CLU, DUSP6, TLR4, 
TNFRSF10A, and CCL2 in FL-MSC compared to HD-MSC. Each sample was 
normalized to GAPDH and the arbitrary value of 1 was assigned to the median 
expression of HD-MSC. * P < .05; *** P < .001. 
 
Figure 2. FL-MSC are committed to a FRC-like phenotype 
(a) Schematic representation of the statistical analysis used to highlight the TNF/LT 
signature defined as the intersection of the two genelists generated by SAM analysis 
(|FC|>2 and false discovery rate (FDR) < .1%) and Mann-Whitney rank test (|FC|>2 
and P < .005). 
(b) Validation by RQ-PCR of the overexpression of TLR4, IL6, HBEGF, IL15, CCL2, 
IL8, and CCL5 in HD-MSC stimulated by TNF/LT for 3 days compared to untreated 
HD-MSC. Each sample was normalized to GAPDH and compared with expression in 
untreated HD-MSC. The results are the mean ± SD obtained on 3 different HD-MSC.  
(c) GSEA Enrichment Score (ES) curves for the TNF/LT signature in MSC samples 
using the SNR statistic to rank the genes. Vertical black lines indicate the position of 
each of the 811 non-redundant upregulated genes included in the TNF/LT signature 
and the green curve represents the running sum of the weighted ES. 
(d) Hierarchical clustering of HD-MSC and FL-MSC performed on the 1673 PS of the 
TNF/LT signature. The relative level of gene expression is depicted according to the 
shown color scale. 
(e) BL2 cell line was cultured in low serum concentration alone, or with confluent HD-
MSC (n=9) or FL-MSC (n=8), pretreated or not with TNF/LT. Tritiated thymidine (3H-
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TdR) incorporation was evaluated at day 3. MSC cultured alone always showed a 3H-
TdR incorporation ≤ 500 cpm. ** P < .01; *** P < .001 
 
Figure 3. CCL2 is overexpressed by FL-MSC and is involved in monocyte 
recruitment 
(a) CCL2 production in culture supernatants from HD-MSC (n=6) and FL-MSC (n=9) 
was quantified by ELISA at the end of P1 and data are normalized by the number of 
cultured MSC. ** P < .01 
(b) CCL2 was quantified in the bone marrow plasma obtained from HD (n=31) and FL 
patients (n=26, including 23 patients with FL grade 1-2 and 3 patients with FL grade 
3a identified as white triangles). *** P < .001 
(c) Migration of purified peripheral blood monocytes in response to HD-MSC and FL-
MSC supernatants collected at the end of P1 and specifically depleted or not from 
CCL2 using magnetic beads. Monocyte migration index is calculated as the number 
of TOPRO-3negCD14pos viable monocytes migrating in response to MSC supernatant 
divided by their number in response to migration medium. Results represent the 
mean ± SD from 3 (HD-MSC) or 4 (FL-MSC) independent experiments. * P < .05 
 
Figure 4. FL-MSC and macrophages cooperate to sustain FL B-cell growth 
(a,b,c) GC-derived B-cell lines were cultured in low serum concentration alone 
(CTRL), in the presence of FL-MSC, in vitro differentiated macrophages (Macro), or 
with a combination of Macro and FL-MSC that have previously established a 
bidirectional crosstalk during a 4-day coculture. (a) Cell growth was evaluated at day 
3 on VAL (Left panel) and RL (Right panel) using tritiated thymidine (3H-TdR) 
incorporation. Results represent the mean ± SD from 6 experiments. MSC and 
macrophages cultured without B cells always showed a 3H-TdR incorporation ≤ 500 
cpm. (b) Apoptosis was evaluated at day 1 on VAL using active caspase-3 staining 
gated on CD19/CD20pos B cells. Results represent the mean ± SD from 6 
experiments. (c) Proliferation was evaluated at day 3 on VAL using BrdU staining 
gated on CD19/CD20pos B cells. Results represent the mean ± SD from 4 
experiments. * P < .05; ** P < .01; *** P < .001; ns: not significant.  
(d) Purified B cells obtained from 4 FL patients were cultured alone (CTRL), in the 
presence of FL-MSC, in vitro differentiated macrophages (Macro), or with a 
combination of Macro and FL-MSC that have previously established a bidirectional 
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crosstalk during a 4-day coculture. The absolute number of B cells was assessed 
using TOPRO-3 staining and calibrated beads. 
** P < .01; *** P < .001. 
 
Figure 5. FL-MSC drive monocyte differentiation to a TAM-like phenotype 
(a) Early modulation of monocyte phenotype and secretory profile was evaluated 
after 24 hours of culture with or without FL-MSC. HLA-DR, CD86, and CD14 
expression was evaluated by flow cytometry on CD14posCD105negTOPRO-3neg viable 
monocytes as the ratio of mean fluorescence intensity (rMFI) compared to isotype 
control (Left panel). The production of TNF and IL-10 in the supernatant was 
simultaneously studied by ELISA (Right panel). Results represent the mean ± SD 
from 5 experiments. * P < .05; *** P < .001. 
(b) Late modulation of macrophage gene expression profile was evaluated after 7 
days of coculture of monocytes with or without FL-MSC before cell sorting of 
CD14posCD105negTOPRO-3neg viable macrophages. Expression of IL10, IL6, VEGFA, 
and PGF was then evaluated by RQ-PCR. Each data was normalized to GAPDH and 
compared with expression in macrophage alone. The results are the mean ± SD from 
9 experiments. * P < .05; ** P < .01; *** P < .001. 
(c) Monocytes were cultured during 7 days with or without FL-MSC before stimulation 
or not by LPS during 5 hours. CD14posCD105negTOPRO-3neg viable macrophages 
were then cell-sorted and expression of TNF, IL10, and IL12A was evaluated by RQ-
PCR. Each sample was normalized to GAPDH and compared with expression in 
unstimulated macrophages. The results are the mean ± SD from 5 experiments.  
* P < .05.  
(d) Monocytes were preincubated or not (MEDIUM) with DAPT or its vehicle (DMSO) 
for 1 hour, and cultured in the same conditions during 7 days with or without FL-MSC. 
LPS was then added or not (CTRL) during 18 hours and TNF concentration was 
measured in cell supernatants by ELISA (n = 10). * P < .05; ** P < .01; *** P < .001; 
ns: not significant. 
 
Figure 6. FL B-cells promote a prolonged CCL2 production by HD-MSC 
(a) HD-MSC were stimulated for 3 days by TNF/LT (n=3), or were cocultured with RL 
(n=5), VAL (n=5) or BL2 (n=4) B-cell lines, or with purified primary FL B cells (n=13). 
Three FL B cells were cocultured with 2 different HD-MSC (green triangles, blue 
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squares, and red circles, respectively). CCL2 concentration was then measured in 
cell supernatants by ELISA and the results are expressed as the mean fold change 
compared to untreated HD-MSC. * P < .05; *** P < .001; ns: not significant. 
(b) HD-MSC were cultured for 3 days with RL or VAL before cell sorting of 
CD19/CD20posCD105negDAPIneg viable B cells and CD19/CD20neg CD105posDAPIneg 
viable MSC and quantification of CCL2 by RQ-PCR in each cell fraction. Same 
experiments were conducted with HD-MSC, RL, and VAL cultured alone. Each CCL2 
Ct value was normalized to matched GAPDH Ct value. The results are the mean ± 
SD from 3 experiments. * P < .05; ** P < .01. 
(c) HD-MSC were cultured for 3 days with RL or VAL before collection of cell 
supernatant (Day 0). HD-MSC were then detached, depleted from residual B cells, 
and seeded again in culture for 10 days. CCL2 concentration was measured in Day 
0, Day 4, and Day 10 cell supernatants by ELISA. Results are expressed as the fold 
change compared to untreated HD-MSC. Shown is one representative from two 
independent experiments. 
(d) Migration of purified peripheral blood monocytes in response to supernatants from 
RL, VAL, HD-MSC, and HD-MSC maintained during 3 days in coculture with RL or 
VAL. Monocyte migration index is calculated as the number of TOPRO-3negCD14pos 
viable monocytes migrating in response to cell supernatant divided by their number in 
response to migration medium. Results represent the mean ± SD from 5 independent 
experiments. * P < .05 
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